Medication Guide App

New Drug Approvals Archive

Get news by email or subscribe to our news feeds.

June 2003

June 12

Uroxatral (alfuzosin) Extended-Release Tablets

Date of Approval: June 12, 2003
Company: Sanofi Synthelabo
Treatment for: Benign Prostatic Hyperplasia

Uroxatral (alfuzosin) an alpha-1-adrenergic receptor antagonist, is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.

June 17

FluMist (Influenza Virus Vaccine, Live, Intranasal)

Date of Approval: June 17, 2003
Company: MedImmune Vaccines, Inc
Treatment for: Influenza Prophylaxis

FluMist is a live trivalent nasally administered vaccine intended for active immunization for the prevention of influenza.

June 20

Xolair (omalizumab) Subcutaneous Injection

Date of Approval: June 20, 2003
Company: Genentech, Inc.
Treatment for: Asthma -- Maintenance, Urticaria

Xolair (omalizumab) is a monoclonal antibody indicated for the treatment of patients with moderate to severe persistent asthma, and chronic idiopathic urticaria.

June 20

Reyataz (atazanavir sulfate) Capsules

Date of Approval: June 20, 2003
Company: Bristol Myers Squibb
Treatment for: HIV Infection

Reyataz is a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection.

June 27

Bexxar (Tositumomab and Iodine I 131 Tositumomab)

Date of Approval: June 27, 2003
Company: Corixa Corporation
Treatment for: non-Hodgkin's Lymphoma

Bexxar is a dual-action therapy that combines the tumor-targeting ability of a cytotoxic monoclonal antibody and the therapeutic potential of radiation. Bexxar is indicated for the treatment of Non-Hodgkin’s lymphoma.

October 2

Reyataz (atazanavir sulfate)

Patient Population Altered: September 30, 2008

November 6

Reyataz (atazanavir sulfate)

Labeling Revision Approved: November 5, 2009

February 7

Reyataz (atazanavir sulfate)

Labeling Revision Approved: February 4, 2011

March 1

FluMist (Influenza Virus Vaccine, Live, Intranasal)

New Formulation Approved: March 1, 2012

March 21

Xolair (omalizumab)

New Indication Approved: March 21, 2014

Hide
(web4)